Billy Dunn, MD, director of the FDA's neuroscience division, left the agency on Feb. 27. Dr. Dunn was part of the cohort that defended Aduhelm, an Alzheimer's drug whose approval has been highly criticized.
"After a long and highly productive career in public service, Billy has decided to retire from FDA and explore other opportunities while continuing his focus on improving the lives of patients with neurological diseases," Peter Stein, MD, director of the agency's office of new drugs and the center for drug evaluation and research, said in an emailed statement.
The FDA named Teresa Buracchio, MD, to be deputy director and acting office director of the neuroscience sector.